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Background: Transforming growth factor β induced (TGFBI) product, an extracellular matrix (ECM) protein, has
been implicated as a putative tumor suppressor in recent studies. Our previous findings revealed that expression of
TGFBI gene is down-regulated in a variety of cancer cell lines and clinical tissue samples. In this study, ectopic
expression of TGFBI was used to ascertain its role as a tumor suppressor and to determine the underlying
mechanism of mesothelioma and breast cancer.
Methods: Cells were stably transfected with pRc/CMV2-TGFBI and pRc/CMV2-empty vector with Lipofectamine Plus.
Ectopic expression of TGFBI was quantified by using quantitative PCR and Western-blotting. Characterization of cell
viability was assessed using growth curve, clonogenic survival and soft agar growth. The potential of tumor
formation was evaluated by an in vivo mouse model. Cell cycle was analyzed via flow cytometry. Expressions of
p21, p53, p16 and p14 were examined using Western-blotting. Senescent cells were sorted by using a Senescence
β-Galactosidase Staining Kit. Telomerase activity was measured using quantitative telomerase detection kit.
Results: In this study, an ectopic expression of TGFBI in two types of cancer cell lines, a mesothelioma cell line
NCI-H28 and a breast cancer cell line MDA-MB-231 was found to have reduced the cellular growth, plating
efficiency, and anchorage-independent growth. The tumorigenicity of these cancer cell lines as determined by
subcutaneous inoculation in nude mice was similarly suppressed by TGFBI expression. Likewise, TGFBI expression
reduced the proportion of S-phase while increased the proportion of G1 phase in these cells. The redistribution of
cell cycle phase after re-expression of TGFBI was correspondent with transiently elevated expression of p21 and
p53. The activities of senescence-associated β-galactosidase and telomerase were enhanced in TGFBI-transfected
cells.
Conclusion: Collectively, these results imply that TGFBI plays a suppressive role in the development of
mesothelioma and breast cancer cells, possibly through inhibitions of cell proliferation, delaying of G1-S phase
transition, and induction of senescence.
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TGFBI, also called Betaig-h3, was first identified during
the 1990s, when it was isolated from a human lung
adenocarcinoma cell line (A549) which had been treated
with TGF-β [1]. The TGFBI protein contains a secretary
signal sequence (residues 1–23), four homologous* Correspondence: tkh1@columbia.edu
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reproduction in any medium, provided the orinternal domains, and a cell attachment (RGD) site [2,3].
TGFBI is secreted into the extracellular matrix (ECM) as
an attachment protein. It functions mainly in cell adhe-
sion, migration, proliferation, apoptosis, and angiogen-
esis [4-11]. Mutations of the TGFBI gene have been
shown to be involved in several corneal dystrophies
[12,13]. TGFBI mRNA and protein are up-regulated in
different types of cell lines, including human epithelial
cells, keratinocytes, lung fibroblasts, and melanoma cells.
More recently, the TGFBI gene has been found to be fre-
quently associated with cancer development. The ex-
pression of TGFBI is either down-regulated or lost in a
variety of human tumor cell lines [4,14,15]. Transfectionhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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marked inhibition of tumor formation in nude mice. Ec-
topic expression of TGFBI in tumorigenic human bron-
chial epithelial cells induced by radiation and asbestos
fibers significantly suppressed the tumorigenicity of
those cells [3,14,16]. Recent findings have suggested that
TGFBI also sensitizes ovarian cancer cells to paclitaxel
by inducing microtubule stabilization and that the loss
of TGFBI induces drug resistance and mitotic spindle
abnormalities in ovarian cancer cells [17].
Malignant pleural mesothelioma (MPM) is an
asbestos-related malignancy characterized by rapid, pro-
gressive, diffused growth and metastasis. The latency be-
tween tumor onset and the first exposure to asbestos or
other carcinogenic fibers is extremely long, averaging
over 30 years. Due to the long latency and extensive his-
tory of the use of asbestos in many industries, the inci-
dence of MPM is expected to increase over the next few
decades. It is estimated that about 2,500–3,000 new
cases arise each year in United States and in Europe. An
estimated 250,000 people will die of MPM in the next
three decades [18,19]. Breast cancer, the most commonFigure 1 Expression of TGFBI mRNA and protein in TGFBI-transfected
transfected with pRc/CMV2-TGFBI and pRc/CMV2-empty vector. The expres
The value was used to plot TGFBI expression using 244Ct. Each value is ex
mesothelioma cells (T2804, T2806, and T2807), pRc/CMV2- vector control ce
immortalized human mesothelial epithelial cell line. (B) TGFBI-transfected b
control cell (V23101), and parental breast tumor cell MDA-MB-231. MCF-10
line. Expression of TGFBI protein in (C) mesothelioma cells and (D) breast t
immunohistochemical staining (lower, ×400).malignancy in women living in western countries, has
also been increasing in the rest of the world [20]. In the
United States, breast cancer is the second most common
cause of cancer deaths in women. Although the mechan-
ism of how these two types of malignancy undergo ma-
lignant transformation remains largely unknown,
evidence indicate a multistep process involving both ac-
tivation of oncogenes and inactivation of tumor suppres-
sor genes exists [21,22] The observation that many late-
stage tumors are highly resistant to traditional chemo-
therapy and radiation therapy, highlights the need for in-
novative therapies based on mechanistic insight of the
cancer process. In this regard, the potential role of
TGFBI as a tumor suppressor may provide a novel target
for manipulation and therapeutic purposes.
Results
Effects of TGFBI on tumor cell growth in vitro
Engineered mesothelioma cell clones (T2804, T2806,
and T2807) and breast cancer cell clones (T23108,
T23109, and T23113) ectopically expressing TGFBI were
generated from their respective parental tumor cell lines,, empty vector control, and parental tumor cells. (A) Cells were
sion of TGFBI mRNA was analyzed by quantitative real-time RT-PCR.
pressed in triplicate (error bars; mean± SD). TGFBI-transfected
lls (V2801), and parental mesothelioma cells NCI-H28. Met-5A is an
reast cancer cells (T23108, T23109 and T23113), pRc/CMV2- vector
F is a spontaneously derived immortalized human breast epithelial cell
umor cells was measured with Western blotting (upper) and
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sentative clones were used for the study (Figure 1). To
characterize the anti-proliferative and tumor suppressive
effects of TGFBI, a growth kinetic study was conducted.
The results demonstrated that the reintroduction of
TGFBI into NCI-H28 and MDA-MB-231 cells dramatic-
ally slowed cell growth and prolonged population doub-
ling time 4.38 and 1.16 times (Figure 2A and 2B),
respectively. TGFBI also significantly reduced relative
plating efficiency (PE), another parameter of cell viabil-
ity. The plating efficiency of human mesothelioma cells
dropped from 98.00% to 29.71%, and that of breast can-
cer cells dropped from 98.8% to 73.28% (Figure 2C).
TGFBI expression inhibited anchorage-independent
growth in these two cancer cell lines, exhibiting a drop
of 48.54% in mesothelioma cells and 90.89% in breast
cancer cells relative to control cells of both types (Fig-
ure 2D). These results suggest that TGFBI modulatesFigure 2 Effects of TGFBI on the growth of tumor cells in vitro. (A) Gro
and T2807), vector control cells (V2801), and parental mesothelioma NCI-H2
(T23108, T23109, and T23113), vector control cells (V23101), and parental b
independent experiments and error bars represent mean± SD. (C) Relative
parental cells, each in triplicate (error bars; mean± SD). (D) Number of colo
each in triplicate (error bars; mean± SD). * # indicates significant decreasescell proliferation and neoplastic transformation
phenotypes.
Effects of TGFBI on tumor development in vivo
To determine whether TGFBI has a tumor-suppressive
effect in vivo, we subcutaneously inoculated TGFBI-
expressing tumor cells and vector control cells (herein
referred as controls) into immuno-deficient nude mice.
Tumor formation was monitored by weekly palpation
and by direct nodule resection. We found that tumor
nodules were palpable as early as 4 weeks after inocula-
tion in the mice injected with vector control breast can-
cer cells. By 5 weeks, 100% of the mice grew tumors,
with an average volume of 448 mm3. In contrast, mice
injected with TGFBI-expressing cells (T23108, T23109,
and T23113) showed signs of tumor growth at 6 weeks
post inoculation, 2 weeks later than control groups. Only
50% of these mice developed tumors by 12 weekswth curves of TGFBI-transfected mesothelioma cells (T2804, T2806,
8 cells. (B) Growth curves of TGFBI-transfected breast cancer cells
reast tumor MDA-MB-231 cells. Data are generated from three
plating efficiencies (PE) of TGFBI expression and vector control cells to
nies expressing TGFBI or vector control relative to parental cells,
relative to vector control cells (*, P< 0.01; #, P< 0.05).
Table 1 Suppression of in vivo tumor growth by ectopic






MDA-MB-231 12/12 }24/24 452.67 ± 114.56 }448.36 ± 107.56
V23113 12/12 444.05 ± 105
T23108 4/8 }12/24* 266± 41.88 }251.85 ± 36.16#
T23109 5/8 264.55 ± 28.94
T23113 3/8 225± 32.69
*, Chi-squared text, P< 0.01, relative to parental and empty vector tumor cells
#, t-test, P< 0.01, relative to parental and empty vector tumor cells.
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252 mm3 (#, P< 0.01).
In order to show the inhibitory effects of TGFBI on
tumor growth at the molecular level, ki67, a molecular
marker of cell proliferative capacity was used to stain
the tissue slides dissected from tumors of each group
[23]. Our results showed that there were significantly
fewer ki67-positive cells in tumor tissues expressing
TGFBI than in tissues without TGFBI (Figure 3). This
supports the assertion that TGFBI inhibits cell prolifera-
tion in vivo.
Effects of TGFBI on G1 phase arrest and S phase delay
To determine whether the suppressive effects of TGFBI
on cell proliferation and subsequent transformation were
due to alterations in cell cycle progression, we comparedFigure 3 Effects of TGFBI on cell proliferation in vivo. Expression of ki6
MDA-MB-231 cells transfected with TGFBI or vector control was assayed us
were observed in ki67-positive cells. (B) Data are shown as the number ofcell cycle profiles between TGFBI-transfected and con-
trol cells in these two types of tumor cell lines. After
serum starvation, both control and TGFBI-expressing
cells were largely arrested in G1 phase, as shown in Fig-
ures 4A and 4B. With serum stimulation, the proportion
of cells in the G1 phase was far lower in control cells
than in TGFBI-expressing cells. (*, P< 0.05). These con-
trol cells began to enter the S phase as early as 4 h after
serum stimulation, but TGFBI-expressing cells did not
begin to enter the S phase before 20 h. Although the
number of TGFBI-expressing mesothelioma cells in the
S phase increased over time, it remained significantly
lower than that of the control cells at all evaluated
points in time, specifically 4, 8, 24, and 32 h after serum
stimulation. Similar changes were observed in breast
cancer cells (#, P< 0.05). When TGFBI was expressed,
the cell proliferation rate (T2807 and T2313) was lower
than that of control cells at 12–24 h after serum stimula-
tion (#, P< 0.05; Figures 4C and 4D). These results
imply that TGFBI-expressing cells may be more resistant
to cell cycle transition (G1-S) than other cells, even
when exposed to external stimulation.
Tumor suppressors p53 and p21 are known to regulate
the G1/S checkpoint. Their expression levels were there-
fore examined in TGFBI-expressing cells and in con-
trols, as shown in Figures 5A and 5B. TGFBI-expressing
cells T2807 and T23113 exhibited elevated p21 and p53
levels at 12 h and up to 24 h upon serum stimulation. In
contrast, their expression in control cells showed less7 in immuno-deficient nude mice subcutaneously injected with
ing immunohistochemical staining. (A) More brown than blue nuclei
ki67 positive cells relative to V23101 cells, *, P< 0.01.
Figure 4 TGFBI during G1 phase arrest and S phase delay. (A) Mesothelioma and (B) breast tumor cell lines with and without re-expressed
TGFBI were collected at different times, cell cycle profiles were assessed by flow cytometry. Line graphs and plots illustrate the distribution of
cells in G1 and S phases over 32 h. Representative proliferation of (C) mesothelioma and (D) breast tumor cell lines with and without TGFBI
re-expression assessed using a CyQUANT NF proliferation kit at the indicated points in time. The proliferation rate is expressed as increased
percentages [(fluorescence intensity at time t-fluorescence intensity at 0 h)/fluorescence intensity at 0 h]. All growth data were generated from
three independent experiments (error bars; mean± SD). * Indicates significant increases over vector control cells (P< 0.05). # Indicates significant
decreases relative to vector control cells (P< 0.05).
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phase entry and that this phenomenon may be asso-
ciated with the up-regulation of p21 and p53.
Effects of TGFBI on cellular senescence
Senescence is an aging state during which cells lose the
ability to divide, which is often controlled by some onco-
genes and tumor suppressors [24-26]. Dysregulation of
senescence can lead to cellular immortalization and ma-
lignant transformation. Senescence-associated β-
galactosidase (SA-β-Gal) has frequently been used as a
marker of cellular senescence, as indicated by histo-
chemical staining at pH 6.0 [27]. In this study, strong
positive staining was observed for β-galactosidase activ-
ity in most of TGFBI-expressing cells, such as T2807and T23113, but not in control cells (Figures 6A and
6B). These results suggest that TGFBI may be involved
in the regulation of cellular senescence. One of the pro-
posed scenarios is that cells are “pushed” into senes-
cence by telomere shortening, which is facilitated by
telomerase activity. Immortalized cell lines and/or tumor
cells gain the ability to maintaining their telomeres
through alternative lengthening mechanisms [28]. Our
data show that the telomerase activity of TGFBI-
expressing mesothelioma cells is significantly higher
than that of controls (P< 0.01, Figure 6C). This is con-
sistent with TGFBI’s hypothesized inhibitory role. How-
ever, two well-known senescence regulators, p16 and
p14, were found to be unaffected by TGFBI re-
expression (Figure 6E). This indicated that TGFBI could
Figure 5 TGFBI up-regulates expression of p53 and p21. (A) Mesothelioma and (B) breast tumor cell lines transfected with vector and TGFBI
were synchronized in quiescence by serum starvation and induced to reenter the cell cycle by the addition of serum. Temporal expression of p53
and p21 in response to serum stimulation were assessed by Western blotting.
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cells with biallelic deletion. In breast cancer cells, neither
the telomerase activity (Figure 6D) nor expression of
p16 and p14 (Figure 6F) changed in response to re-
expression of TGFBI.
Discussion
TGFBI, an extracellular secreted matrix protein, was ori-
ginally implicated as a regulator of cell adhesion and mi-
gration. More recently, down-regulation of TGFBI
expression has been reported to be involved in the de-
velopment of human tumors, including lung, breast,
ovarian, prostate, embryonic rhabdomyosarcoma, insuli-
noma, and mesenchymal tumors [14,16,29-33]. Loss of
TGFBI expression has also been observed in neoplastic
transformation in CHO cells and papillomavirus-
immortalized human bronchial epithelial cells [3,14,16].
The physiological role of TGFBI is still largely un-
known. It has been reported that the embryonic expres-
sion of TGFBI is particularly strong in the mesenchyme
of many tissues throughout all stages of development
[34]. In addition, immunohistochemical analysis has
demonstrated that TGFBI proteins are deposited in
ECM and in cytoplasm and nuclei. Analyses of medium
and matrix fractions displayed a protein at 70–74 kDa,
and nuclear extracts showed a 65 kDa reactive protein
band [35]. We also found that TGFBI protein localized
not only in cell culture medium and cytoplasm, but also
in the nuclei of TGFBI-transfected tumor cells and
immortalized epithelial cells (Met-5A cells and MCF-
10 F cells). The diverse distribution of TGFBI suggeststhat the functions of TGFBI may not be limited to its
role as a component of ECM.
The FAS1 domains of TGFBI have been shown to in-
hibit tumor angiogenesis and tumor growth and to pro-
mote apoptosis. This is also consistent with a tumor
suppressor role for TGFBI [36]. Recent evidence has
shown that TGFBI expression causes significantly higher
sensitivity to apoptotic induction by upregulation of
IGFBP3 [29]. It also repressed tumor cell invasion, pos-
sibly by suppressing the PI3K/Akt/mTOR signaling
pathway [37]. Loss of TGFBI expression is frequent in
human cancer and it has been causally related to acqui-
sition of tumorigenic phenotype in asbestos-treated
immortalized human bronchial epithelial cells. In this
study, by re-introduction of TGFBI into tumor cell lines
MDA-MB-231 and NCI-H28, which have naturally low
levels of TGFBI, we substantiated the role of TGFBI as a
tumor suppressor and more importantly discovered pre-
viously unknown portions of its underlying mechanism.
Our data show that TGFBI significantly reduced cell
growth rate, plating efficiency, and anchorage-
independent growth. These parameters are often used to
assess the fundamental characteristics linked to the
functions of oncogenes and tumor suppressors. The
results are consistent with proposed biological functions
of TGFBI and results obtained from this and previous
studies [1,36]. Cell cycle progression through G1 phase
into S phase is a major checkpoint for cells during pro-
liferation. Dysregulation of the G1/S transition may ar-
rest the cells in quiescence or drive them into nonstop
proliferation, depending on the specific scenario. A
Figure 6 TGFBI induces cellular senescence. (A) Mesothelioma and (B) breast cancer cell lines with and without re-expression of TGFBI were
sub-cultured and then maintained for 2 days in growth medium prior to assay for SA-β-Gal staining. Most of the T2807 and T2313 cells were
SA-β–Gal-positive (right panels of A, B, ×200), and most of the V2801 and V23113 cells were SA-β–Gal-negative (left panels of A, B, ×200).
(C) Mesothelioma and (D) breast tumor cell extracts were prepared, and telomerase activity was assayed using QTD real-time PCR. Data are
shown as the threshold cycle (Ct) of real-time PCR relative to vector control cells, *, P< 0.01. Expression of p16 and p14 in (E) mesothelioma and
(F) breast tumor cells was assessed by Western blotting with whole-cell lysates from harvested cells.
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G1/S transition directly or indirectly, notably cyclin A1,
p21, and p53 [38]. Data from this study demonstrates
that TGFBI upregulates p53 and p21. This suggests that
the inhibitory effect of TGFBI on this checkpoint may
be related to these two molecules.
Earlier, our group presented evidence that TGFBI defi-
ciency can lead to mutations, chromosomal fragmenta-
tion, and genetic instability, which in turn promotes
tumor development. Similarly, ablation of TGFBI
increases the frequency of chromosomal aberration and
micronuclear formation, as observed in fibroblast cells
isolated from TGFBI knock-out mice. However, these
cells also showed more proliferation and earlier entry
into S-phase entry than those of wild-type mice [39]. In
this study we did not check for genetic instability but ra-
ther precisely reproduced the evidence of TGFBI’s in-
hibitory effects on cell proliferation, transformation, and
G1/S transition using a different model, which strongly
supported the conclusion that TGFBI is a tumorsuppressor. It may execute its function by modulating or
interacting with other cell cycle effectors, ultimately
leading to unchecked cell proliferation and malignant
transformation.
Cellular senescence is defined as a state of irreversible
arrest in cell division after a period of serial proliferation
in normal diploid cells [40]. It can also serve as a stress
protective response. It can be triggered by a number of
sensing mechanisms, such as telomere shortening, epi-
genetic derepression of the INK4a/ARF locus that
encodes two physically linked tumor suppressor proteins
p16/p14, and DNA damage [41]. p16 has been shown to
inhibit the ability of cyclin D1 to hinder S-phase entry,
which is one of the possible mechanisms involved in the
regulation of cellular senescence [42]. Escaping senes-
cence is a prerequisite for cell immortalization and
transformation [43-45]. We therefore asked if TGFBI’s
inhibitory effect on cellular transformation (anchorage-
independent growth and malignancy) is related to its
modulation of senescence. To our surprise, an enhanced
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was evidenced by the increased levels of SA-β-gal, a clas-
sic marker of cellular senescence.
Elevation of telomerase activity, another sign of senes-
cence, however, exhibited different pattern in mesotheli-
oma and breast cancer cells. In NCI-H28 cells,
telomerase activity increased significantly with the ex-
pression of TGFBI, which directs cells into senescence.
The loss of TGFBI is therefore believed to contribute to
the escape of cells from senescence. However, TGFBI
did not affect telomerase activity in MDA-MB-231 cells.
The expression of p16 and p14 showed no significant
difference between TGFBI-expressing and control cells.
Homozygous deletion of the p16 gene has been reported
in 85% of mesothelioma cell lines, including NCI-H28
cells and 22% of primary tumor specimens [46,47]. This
makes it difficult to assess the functional association be-
tween TGFBI and p16. Other mechanisms may be
involved in controlling the process, p21 and p53 are po-
tential candidates [48,49]. In both types of cells, p21 and
p53 were both up-regulated upon TGFBI expression.
Our results clearly showed that SA-β-gal and telomerase
activity were both up-regulated by TGFBI re-expression.
This may suggest that TGFBI carries out its inhibitory
functions on cellular senescence involving p21 and p53.
Further results derived from in vivo substantiated the
role of TGFBI as a tumor suppressor. After implanting
cells with TGFBI and leaving others without, we ana-
lyzed the onset, incidence, and volume of the resulting
tumors in mice, in order to assess the tumor suppressive
effect of TGFBI. Although TGFBI did not completely
block the formation of tumors derived from injection of
MDA-MB-231 cells, the onset of tumor formation was
delayed, tumor volume was greatly reduced, and the
number of tumors decreased dramatically. This is in ac-
cordance with our previous data, which showed that
TGFBI suppresses tumorigenic phenotypes in lung and
human bronchial epithelial cells induced by radiation
and asbestos [14,16,29]. Unfortunately, both TGFBI-
expressing and vector control meosthelioma cells failed
to produce progressively growing tumors even at 5
months after cell inoculation. We are not sure what the
exact reason for this may be. One explanation could be
that the residual immunity of nude mice may still be
able to reject some types of cells. One alternative means
of evaluating these phenomena would be to use SCID
mice, which lack both T and B lymphocytes, unlike nude
mice, which only lack T cells. For further evaluation of
the inhibitory role of TGFBI on a molecular level, tissue
slides dissected from tumors in each group were stained
with the nuclear antigen ki67, which serves as a marker
of cellular proliferation capacity [23,50]. The number of
ki67-positive cells inversely correlated with the level of
TGFBI expression; the more ki67-positive cells observedin the vector control groups, the stronger the evidence
that TGFBI diminishes the ability of cells to proliferate
and therefore inhibits tumorigenicity in vivo. We here
present strong evidence that unequivocally supports that
TGFBI exhibits an inhibitory effect on tumor growth
both in vitro and in vivo, especially in mesothelioma and
breast cancer cells.
Contrary evidence from other groups was brought into
our attention. For example, it has been suggested that
TGFBI increases the metastatic ability of colon and an
ovarian cancer cell lines [51,52] In addition, TGFBI has
been shown to be over-expressed in pancreatic cancer,
renal cell carcinoma and glioblastoma [53-55]. It is likely
that TGFBI protein may function in multiple ways de-
pending on tissue type and tumor microenvironment.
TGFBI gene is a downstream target of transforming
growth factor beta (TGF-β) that inhibits the proliferating
of normal epithelial cells and functions as a tumor sup-
pressor in early tumorigenesis as well as a tumor pro-
moter in later stage of tumor progression. This stage-
specific dual functional role of TGFBI in cancer repre-
sents an emerging paradigm whereas the mechanism be-
hind is not well understood. We are planning to expand
our research to more type of cell lines and clinical sam-
ples. Our particular focus will be on the questions left
unanswered by this and other reports.Conclusion
In summary, our study is the first to show that TGFBI
inhibits cell proliferation and transformation by delaying
G1-S phase transition and inducing cellular senescence
in mesothelioma and breast cancer cells, indicating that
TGFBI may serve as a negative regulatory effector and
potential tumor suppressor in the development of malig-
nances such as mesothelioma and breast cancer. Our
findings may offer a new vision for the management of
certain types of cancers.Methods
Cell culture and stable transfection of TGFBI
Human malignant pleural mesothelioma cell line (NCI-
H28) and a breast tumor cell line (MDA-MB-231) were
obtained from the American Type Culture Collection
(ATCC; Manassas, VA, U.S.) and grown in Dulbecco’s
Modified Eagle medium (DMEM) supplemented with
10% fetal bovine serum (FBS). Cells were plated into 6-
well plates and transfected with either pRc/CMV2-
TGFBI or pRc/CMV2-empty vector with Lipofectamine
Plus (Invitrogen, Carlsbad, CA, U.S.). The cells were
split at 1:10 and cultured in medium containing 700 μg/
ml of G418 (Sigma-Aldrich, St. Louis, MO, U.S.) for 21
d. Resistant colonies were isolated, expanded in cultures,
and maintained in the presence of 300 μg/ml of G418.
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quantitative real-time reverse transcription-PCR (RT-
PCR; Applied Biosystems 7300, Foster City, CA, U.S.)
using a RT2 Real-time SYBR Green/ROX Gene Expres-
sion Assay Kit (SuperArray Bioscience Corp., Frederick,
MD, U.S.). The first strand of cDNA was synthesized
from 4 μg total RNA using SuperScript II First-Strand
Synthesis System (Invitrogen). Relative quantification of
TGFBI mRNA expression was performed using real-
time PCR. A comparative threshold cycle (Ct) was used
to determine the expression level. The expression levels
of TGFBI mRNA were expressed as an n-fold difference
relative to the calibrator. Briefly, the TGFBI mRNA Ct
value was normalized using the following formula: △Ct =
CtTGFBI - CtGAPDH. To determine relative expression
levels, the following formula was used: △△Ct =△Ctsam-
ple - △Ctcalibrator. The resulting values were used to plot
the TGFBI expression using the expression 2△△Ct.
Expression of the TGFBI protein in the supernatant of
cells was confirmed by Western blotting. Cells were pla-
ted and grown in DMEM with 10% FBS for 24 h. They
were then transferred to serum-free medium and main-
tained for another 24 h. The medium was then harvested
and trichloroacetic acid (TCA) was added to a final con-
centration of 10%. It was then incubated at RT for
30 min, centrifuged with 13,000 rpm at 4°C for 30 min,
and the supernatant was aspirated. The pellet was
washed three times with acetone and then air dried. Fifty
microliters of laemmli sample buffer was added to the
pellet and boiled for 5 min. It was then resolved on
SDS-PAGE. The gels were transferred onto PVDF mem-
brane and incubated serially with monoclonal anti-
human TGFBI (R&D Systems, Minneapolis, MN, U.S.)
followed by sheep anti-mouse IgG conjugated with
horseradish peroxidase as secondary antibody (Amer-
sham Biosciences, Piscataway, NJ, U.S.). Multiple clones
were chosen for the study, and similar results were
observed with each. The results shown in this manu-
script are representatives of the findings.
Immunohistochemical staining
The expression of TGFBI and Ki-67 was measured by
immunohistochemical staining. Cells were fixed in 4%
paraformaldehyde and then incubated in 0.3% hydrogen
peroxide in absolute methanol for 30 min to quench the
endogenous peroxide activity. Immunostaining was per-
formed with aVestastain Elite ABC Kit (Vector Laborator-
ies, Burlingame, CA, U.S.). Briefly, the slides were blocked
with horse serum for 30 min and then incubated with
anti-human TGFBI antibody or anti-mouse Ki-67 anti-
body (Santa Cruz Biotechnology, CA, U.S.) overnight at 4°
C. After washing with PBS, biotin-conjugated secondary
antibody was applied to the slides for 30 min, followed by
avidin-biotin-peroxidase complex for 30 min. The slideswere then exposed to a reaction solution containing the
chromogen, 3,3′-diaminobenzidine (DAB) for 6 min,
washed with distilled water, and counterstained with
Meyer’s hematoxylin for 10 s. The slides were dehydrated,
cleared, and mounted. The slides were examined and rep-
resentative pictures were captured using an Olympus B ×
60 camera. More brown nuclei than blue were noted for
ki67-positive cells. Five hundred cells on each slide were
evaluated using 40× magnification over the hotspot. Data
are shown as number of ki67 positive cells relative to the
number of V23101 cells, *, P< 0.01.
Growth curve assay
Five thousand cells were plated in 35 mm dishes in
complete medium. The medium was changed every
3 days. At specific points in time after plating (Days 0, 1,
2, 3, 5, 7, 11, and 13), cells were trypsinized and the
number of cells was determined using a Coulter Counter
(Beckman Coulter Inc. Miami, FL, U.S.). The doubling
time of the culture was analyzed using the formula: Nt =
N0 2
tf; doubling time = 1/f; Nt: number of cells at time t;
N0: initial number of cells; t: time (days); f: frequency of
cell cycles per unit time.
Clonogenic survival assay
Cells were trypsinized and counted with a Coulter
Counter. Aliquots of the cells were seeded into dishes
100 mm in diameter. After two weeks of incubation at
37°C and 5% CO2, the colonies formed were fixed with
formaldehyde, stained with Giemsa, and counted using
an Oxford Optronix Colony Counter (Oxford Optronix
Company, UK). The relative plating efficiencies (PE)
were determined using the following formula: Relative
PE = number of colonies of TGFBI expression or vector
control cells / number of colonies of parental cells.
Soft agar assay
Two thousand cells were mixed with 1 mL of 0.35%
agarose and plated into 35 mm dishes with a bottom
layer of 0.75% agarose. Cells were fed every 3 days with
1 ml culture medium. The colonies were counted two
weeks after initial plating. Data are presented as ratio of
number of colonies of TGFBI expression or vector con-
trol cells / number of colonies of parental cells. Data
points in figures represent three independent
experiments.
Cell cycle analysis
Cells were arrested in quiescence by serum starvation in
serum-free DMEM medium supplemented with 1% bo-
vine serum albumin (BSA) for 36 h. Cells were stimu-
lated to reenter the cell cycle by replenishing with fresh
medium containing 10% serum. At different points in
time after serum stimulation, cells were fixed with ice
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iodide (PI) and analyzed using a FACSCalibur flow cyt-
ometer (BD Biosciences, San Jose, CA, U.S.). Line graphs
and plots illustrate the distribution of cells in the G1
and S phases over a period of 32 h. Comparisons be-
tween TGFBI-transfected cells and empty control cells
were determined using the Student’s t-test. *, P <0.05
was considered to be significant.
Cell proliferation assay
Proliferation was assessed by CyQUANT NF Cell Prolif-
eration Assay according to the manufacturer’s instruc-
tions (Invitrogen, Molecular Probes, Inc. Eugene, OR, U.
S.). Briefly, after 0, 12, 16, 20, and 24 h of serum stimula-
tion, cells were washed with PBS and incubated for 1 h
with the fluorescence substrate. Fluorescence intensity
was measured on an automatic microplate reader (Bio-
Tec, Winooski, VT, U.S.). Data are shown as in percen-
tages: [(fluorescence intensity at time t – fluorescence
intensity at 0 h) / fluorescence intensity at 0 h] * 100%.
Western blotting
Proteins were extracted with lysis buffer (50 mM Tris–
HCl, pH 8.0, 150 mM NaCl, 1% NP-40, 0.1% sodium
dodecyl sulfate, 1 mM phenylmethylsulfonyl fluoride
and protease inhibitor cocktails). Protein concentrations
were determined using the Bio-Rad protein Assay (Bio-
Rad, Hercules, CA, U.S.). Equal amounts of protein
(30 μg) were fractionated by SDS-PAGE and transferred
onto PVDF membranes under semi-dry conditions.
Antibodies against p21, p53, p16, p14, and β-actin were
obtained from Cell Signaling Technology, Inc. (Danvers,
MA, U.S.). Secondary antibodies were purchased from
Amersham Biosciences and signals were detected using
an enhanced chemiluminescence (ECL) method accord-
ing to the manufacturer’s instructions (Amersham Bios-
ciences, Piscataway, NJ, U.S.).
Senescence associated β-galactosidase staining
Senescent cells were detected using a Senescence β-
Galactosidase Staining Kit (Cell Signaling Technology
Inc, MA, U.S.). Briefly, cell monolayers were washed
twice with PBS and then fixed with fixative solution for
15 min. The cells were then washed twice with PBS.
Staining solution (930 μl Staining Solution; 10 μl Stain-
ing Supplement A; 10 μl Staining Supplement B; 50 μl
20 mg/ml X-gal in DMF) was applied and then the cells
were incubated at 37°C for 16 h. After incubation, the
cells were washed twice with PBS and photographed
using an Olympus camera.
Telomerase activity
Telomerase activity was evaluated using quantitative tel-
omerase detection kit (QTD kit, US Biomax, Inc, MD,U.S.). Briefly, cells were lysed in 1 × lysis buffer and
incubated at 4°C for 30 min. The lysate was then centri-
fuged at 12,000 × g for 20 min at 4°C, and the super-
natant was collected. The protein concentration of the
cell lysate was determined using a Bio-Rad protein
Assay. Standards, inactivated samples, and template-free
reactions were also assayed on every plate for quality
control purposes. Each sample was analyzed in triplicate.
Real-time amplifications were performed on an ABI
Prism 7300 Sequence Detection System (Applied Biosys-
tems, CA, U.S.). A comparative threshold cycle (Ct) was
used to determine telomerase activity, which is nega-
tively related to the Ct of real-time PCR.
Tumorigenicity in vivo
Male Nu/Nu mice (purchased from Harlan Sprague–
Dawley, Inc. Indianapolis, IN, U.S.) were housed under
pathogen-free conditions. The animals were lightly
anesthetized with isoflurane, and then 5×106 of parental,
vector control, and TGFBI-transfected tumor cells were
injected subcutaneously into the left and right flanks of
each animal (Anaquest, Madison, WI, U.S.). Animals
were maintained under sterile conditions for 5 months
and palpated weekly for tumor formation. Animals were
killed as soon as tumor nodules reached a size of 0.5–
0.8 cm. All animal studies were conducted at Columbia
University under strict Institutional Animal Care and
Use Committee-approved protocols.
Statistical analysis
Data are presented as mean ± standard deviation (SD).
Data were subjected to one way analysis of variance
(ANOVA) and comparisons between TGFBI-transfected
cells and empty vector control cells were determined
using the Student’s t-test. Differences were considered
statistically significant at P <0.05.
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